Lamivudine Treatment Failure Risks in Chronic Hepatitis B Patients with Low Viral Load

Basit Öğe Kaydı
dc.authoridCoban, Sahin/0000-0002-6886-7474
dc.contributor.authorKoklu, Seyfettin
dc.contributor.authorGulsen, Murat Taner
dc.contributor.authorTuna, Yasar
dc.contributor.authorKoklu, Hayretdin
dc.contributor.authorYuksel, Osman
dc.contributor.authorYilmaz, Bans
dc.contributor.authorKaraca, Cetin
dc.date.accessioned2024-09-18T20:26:40Z
dc.date.available2024-09-18T20:26:40Z
dc.date.issued2013
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractAim: To analyze the risk factors of lamivudine treatment failure (LTF) for the long-term use in patients with low viral load (LVL). Material and Methods: In this multicenter study, 548 antiviral nave noncirrhotic adult patients with LVL (for HBeAg+ patients HBV DNA <10(9) copies/ml and for HBeAg patients HBV DNA <10(7) copies/ml) were enrolled. As a control group, 46 lamivudine-initiated patients with high viral load (HVL) were included. Primary outcome was switching to or adding on another antiviral drug as a consequence of primary nonresponse, partial response, viral breakthrough or adverse events. Secondary outcomes included LTF rates at 1, 2, 3, 4 and 5 years and LTF-related viral and host factors. Results: Among 594 patients, 294 had to change lamivudine at the follow-up. Primary nonresponse, partial response, viral breakthrough or adverse events frequencies were 6.8, 1.6, 64.5 and 0.1%, respectively. Five-year LTF rates were 61.3 and 84.2% in patients with LVL and HVL, respectively. Among patients with LVL, patients with <100,000 copies/all and >= 100,000 copies/ml had 54.8 and 67.3% LTF rates at the end of the 5th year, respectively. Logistic regression analysis of risk factors showed HBeAg+, hepatic activity index, HBV DNA, virological response at 6 months and duration of follow-up were independent predictors for LTF (p values were 0.001, 0.008, 0.003, 0.020 and 0.003, respectively). Conclusion: Similar to patients with HVL, first-line lamivudine therapy is not efficient for long-term use in patients with LVL. LTF risk is so high even in the absence of worse predictive factors. (C) 2013 S. Karger AG, Baselen_US
dc.identifier.doi10.1159/000356312
dc.identifier.endpage271en_US
dc.identifier.issn0012-2823
dc.identifier.issn1421-9867
dc.identifier.issue4en_US
dc.identifier.pmid24356645en_US
dc.identifier.scopus2-s2.0-84892165739en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage266en_US
dc.identifier.urihttps://doi.org/10.1159/000356312
dc.identifier.urihttps://hdl.handle.net/20.500.12483/10474
dc.identifier.volume88en_US
dc.identifier.wosWOS:000329275800009en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherKargeren_US
dc.relation.ispartofDigestionen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectHepatitis B virusen_US
dc.subjectLamivudineen_US
dc.subjectResistanceen_US
dc.subjectViral loaden_US
dc.titleLamivudine Treatment Failure Risks in Chronic Hepatitis B Patients with Low Viral Loaden_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ N/A ]
İsim:
Tam Metin / Full Text
Boyut:
194.51 KB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu